(ETX Studio) – A new study suggests that the different stages of menopause may affect cognitive performance until postmenopause, especially in women with HIV and in precarious economic situations.
Appeared in the newspaper Menopause, the results of this study suggest that cognitive declines can appear as early as the perimenopause phase (onset of menstrual irregularity) and continue into the postmenopausal period, that is, after permanent cessation rules. This cognitive dysfunction would therefore occur independently of other known symptoms of menopause such as depression, anxiety and hot flashes.
Much previous research has been done specifically on memory loss associated with menopause. But, note the authors of the work, many of them describe these cognitive changes during perimenopause (the average duration is estimated at 4 years), which suggests that these cognitive disorders could resolve themselves during the period. post-menopause.
However, this new study carried out on more than 440 women with low incomes, some of whom are HIV-positive, shows that difficulties in memorizing everyday things or learning disabilities persist even once menopause has set in.
According to the researchers, this prolonged duration of cognitive decline could be explained by the socio-economic situation of the participants, as well as their state of health. Indeed, the medical literature confirms that factors such as HIV, a precarious economic situation, a low level of education, addictions, high levels of stress or even limited access to quality health care, can promote the risk of cognitive dysfunction.
“This study, which involved a racially diverse sample of low-income women and HIV-positive women, adds to the existing literature on cognitive changes during the menopause transition and showed significant cognitive decline in l learning and memory that persisted until postmenopause. Further research is needed to confirm these findings and to identify the factors responsible for individual differences in cognitive changes, “said Dr. Stéphanie Faubion, medical director of the North American Menopause Society, who led the study.